Author(s): Muselmani W, Habbal W, Monem F
Abstract Share this page
Abstract BACKGROUND: Hepatitis B virus (HBV) transmission via hepatitis B surface antigen (HBsAg)-negative blood donors has been reported. While many countries have implemented screening antibodies to hepatitis B core antigen (anti-HBc) to further enhance transfusion safety, HBsAg is still the only obligatory HBV screening test of blood donors in Syria. OBJECTIVE: To evaluate the significance of screening anti-HBc to reduce the risk of transfusion transmitted HBV infection in Syria. METHODS/MATERIALS: A cohort cross-sectional prospective study included 1939 healthy blood donors assigned at the blood transfusion center of Damascus University. All donors were tested for HBsAg and anti-HBc. HBsAg-negative, anti-HBc-positive sera were further tested quantitatively for antibodies to hepatitis B surface antigen (anti-HBs) and 'anti-HBc alone' sera were considered for HBV quantitative real time polymerase chain reaction (qPCR). RESULTS: Among 1913 HBsAg-negative donors, 215 (11·2\%) were anti-HBc-positive including 125 anti-HBs high-positive and 59 anti-HBs low-positive donors. The remaining 31 donors were 'anti-HBc alone', five of which were HBV DNA-positive. CONCLUSION: Our results suggest including anti-HBc as an additional screening test for blood donors in Syria to reduce the risk of HBV transmission. As the most cost-effective measure, anti-HBc-positive donors should be tested quantitatively for anti-HBs and only donors with no or low (<100 IU L(-1) ) anti-HBs should be deferred. © 2013 The Authors. Transfusion Medicine © 2013 British Blood Transfusion Society.
This article was published in Transfus Med
and referenced in Journal of Infectious Diseases & Therapy